Synergy of tumor necrosis factor with protein kinase C activators on T cell activation
The overexpression of arginine methyltransferase 5 (PRMT5) in solid and hematological tumors leads to the elevation of the methylation level of arginine residues on functionally related proteins in tumor cells, which affects cell cycle regulation, mRNA splicing, cell differentiation, signal transduction, and other physiological processes
A senior who loses 15 to 20 percent of body weight over 18 months, improves blood pressure, reduces cardiovascular risk, and gains mobility and then loses access to the drug faces both health consequences and the prospect of paying list prices that currently exceed $1,000 per month
[Business Group on Health research shows] 73% of employers planned to cover GLP-1s to treat obesity in 2026
Active cancer is a contraindication for most growth-factor-adjacent peptides because we do not want to fertilize a tumor we do not know about